Reimbursement Past Sema denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for reimbursement past sema are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Semaglutide Reimbursement as "Not FDA-Approved"

Semaglutide has received FDA approval for specific indications — but Aetna's system may generate a "not FDA-approved" denial when the submitted diagnosis code, the specific formulation, or the route of administration does not align precisely with the labeled indication on file. Compounded semaglutide products, off-label uses, or minor coding mismatches are the most common triggers.

## Why This Denial Is Appealable

If your prescriber is using an FDA-approved branded formulation for a labeled indication, the denial is almost certainly administrative in nature — a mismatch between what was billed and what Aetna's system recognizes — rather than a genuine clinical coverage question. That makes it highly correctable on appeal. Even where use is off-label, many off-label uses are supported by established clinical guidelines, and Aetna's own medical-necessity criteria may separately cover such uses; that pathway remains open.

## Federal Appeal Framework

• Internal appeal: Under ACA §2719 and ERISA §503 (for employer-sponsored plans), you have the right to a full-and-fair internal review. Submit within the timeframe stated in your denial letter (typically 180 days).
• External review: If the internal appeal is denied, you may escalate to an independent external review organization within approximately four months of the final internal denial. The external reviewer is not employed by Aetna and must apply clinical standards, not Aetna's internal policy alone.
• Expedited review: If your condition is urgent, request an expedited appeal simultaneously with the standard track.

## Documentation to Gather

1. FDA labeling confirmation — obtain the current FDA-approved prescribing information for the exact branded product dispensed, confirming the indication and formulation match what was prescribed. 2. Diagnosis documentation — chart notes, ICD codes, and specialist letters confirming the diagnosis that supports the labeled indication. 3. Prescriber letter of medical necessity — the prescribing clinician should state the specific FDA-approved indication, the formulation prescribed, and why this patient's clinical situation meets the labeled criteria. 4. Pharmacy records — confirm the dispensed NDC corresponds to an approved product, not a compounded alternative.

## Criteria-Mapping Structure

Build a side-by-side table:

| Aetna / FDA Requirement | Patient Chart Evidence | |---|---| | FDA-approved indication (copy exact language from the label) | Chart note date + ICD code | | Approved formulation / route of administration | Prescription + dispensed NDC | | Any additional coverage criteria from Aetna's published medical policy | Corresponding chart documentation |

Retrieve Aetna's current coverage policy for semaglutide directly from Aetna's provider portal or policy library; policy language and criteria change, and your appeal must match the version in effect on the date of service.